Ocular Therapeutix Inc (OCUL)

Ocular Therapeutix price target raised to $28 from $21 at Clear Street

March 2, 2026

Clear Street raised the firm’s price target on Ocular Therapeutix (OCUL) to $28 from $21 and keeps a Buy rating on the shares after the company presented detailed data from the SOL-1 superiority trial in wet age-related macular degeneration. The efficacy data was “consistently positive” and bolstered the claim that Axpaxli “offers durable control of wAMD,” the analyst tells investors in a research note. Clear believes Axpaxli is a “major improvement” in the largest unmet need of dosing interval in a $14B global wet AMD market, with “clean” safety and tolerability.

https://www.tipranks.com/news/the-fly/ocular-therapeutix-price-target-raised-to-28-from-21-at-clear-street-thefly-news

$OCUL 🗞️

Kiwi I saw on another board that you haved exited OCUL.  I am guessing the 60k share purchase by a director a week ago did not impress you. I had doubled my position when the stock dropped and am looking to sell those shares on any kind of strength over the next couple of sessions. Good luck with your other eye investments. 

Thx interesting

Kiwi

Jbog on Dew's biotech values board has just posted that Citizens says the selloff in OCUL brings an attractive entry point, and that the market is losing "the forest through the trees". Also Jeffries stays constructive and maintains a price target of $28. Citizens has a target of $34.

Above my knowledge base, but you are wondering about how this applies or portends for EYPT. There is a poster on Dew's board that seems fairly knowledgeable and he made this comment:

Rescue free by Sol-R standards at week 24 were roughly the same as the US P1 actual and Sol-R should show much better rates by trial design. The read through to EYPT should actually be negative for their program and I'm not seeing it in market reaction.

Now it could that EYPT's stock rose today simply because a competitor of theirs (OCUL) delivered trial results that were not very well received by the market. And possibly by some who dumped OCUL today and bought into EYPT wanting to stay in the space. Sometimes it is not the market reaction on the day of events, but thereafter. I have seen that with Fed market actions. Just have to see what OCUL has to say when they present the full data.

I have small positions in OCUL and EYPT . Larger position in KOD
re EYPT
Whalatane
Re: Stumblebum post# 645
Thursday, December 04, 2025 1:05:39 PM
Post# of 651
Stumble ...You still in this ?
I have a position in OCUL but added EYPT based on clean DSMB review and I think they may actually beat OCUL to FDA approval
Kiwi
I was surprised by how far off OCUL were on the performance of Eyelea ...and am also surprised that EYPT is up 15% in response to the OCUL data .
Based on my limited understanding its unlikely OCUL finds more than a niche market .
What about EYPT ?
Will they produce better results and in fact beat OCUL to market .
That where I'm at now . KOD is still my biggest position of the 3 largely because the Baker Bros are so invested in it . .
EYPT trial's enrolled fast with data mid year .
Todays loss in OCUL fortunately largely wiped out by gains in EYPT and KOD in my portfolio ....but still don't have any conviction of how EYPT data will ultimately read out .
JMO
Kiwi

They still seem to think that they can apply for approval with this and get it.  Thinking at this point that selling is overdone and averaged down with a much lower objective to ultimately get out

Agree The Eyelea arm did far better then expected ...at least based on their modeling .
So....so much for their modeling .
Kiwi

Thanks, I will have a look. 

Ocular Therapeutix plunges 35% despite positive wet AMD Phase 3 dataFebruary 17, 2026 10:35 AM
IH Market News
Ocular Therapeutix Inc. (NASDAQ:OCUL) shares dropped 35% on Tuesday even after the company announced favorable results from its Phase 3 superiority study of AXPAXLI in patients with wet age-related macular degeneration (wet AMD).The biotech group said AXPAXLI achieved the primary endpoint in the SOL-1 trial, showing superiority over aflibercept in preserving vision at Week 36. According to the company, 74.1% of patients treated with AXPAXLI maintained vision at that point, reflecting a 17.5% risk difference compared with the aflibercept group (p=0.0006).At Week 52, 65.9% of participants receiving AXPAXLI maintained vision, while 68.8% remained free from rescue treatment. Management also noted that the therapy was generally well tolerated, with no treatment-related serious ocular adverse events reported.Ocular said it intends to file a New Drug Application (NDA) based on the SOL-1 findings, pending discussions with the U.S. Food and Drug Administration. If approved, AXPAXLI would be the first tyrosine kinase inhibitor brought to market for wet AMD.Despite the headline-positive outcome, investors appeared to focus on potential concerns within the dataset or possible regulatory uncertainties, triggering the sharp selloff.The company is also advancing its complementary SOL-R Phase 3 non-inferiority study, with topline results anticipated in the first quarter of 2027.Comprehensive data from the SOL-1 trial are scheduled to be presented at the 49th Macula Society Annual Meeting later this month.Ocular Therapeutix stock price

Original: Ocular Therapeutix plunges 35% despite positive wet AMD Phase 3 data

Well it seems there still is some buyout believers….. the option prices are still at a premium

Always seems to be. Actually although the trial showed superiority the question is whether it was superior enough to get prescribing habits to change.  

Disregarding any buyout rumors the pr released was positive from what I read….sell on news again ?

I read and think too much. Should have gone with my gut reaction. That being that over the weekend and this morning premarket, it seemed to me that the stock should have been trading much higher than $12. It had already turned down a $16 offer, and the thought was that results would be great since they were releasing before the market on a Tuesday. So it bothered me that the stock was not more than $12. I should have seen that as a warning sign and sold. But, but. but.

Well kind of a waste getting up early today unless someone wanted to avg down or was a short.  Maybe they should have released on Friday. 

Yep

Yep. A problem with Eyelea is that after about 2 yrs use scaring has developed in the back of the eye that can cause total vision loss ...IIRC
If Axapili / ( OCUL ) only lasts 6 mths it faces competition from others in use that may last 4 mths ...for majority of patients .
The idea being that MD's less likely to switch to something new for limited increase in time between shots
Kiwi

In comparison to Eyelea’s 20% at 9 months right?

Saw this back in mid Jan

In late 2025 and January 2026, Sanofi emerged as the primary suitor for Ocular Therapeutix.

The Motivation: Sanofi is targeting Ocular’s lead asset, AXPAXLI (an axitinib hydrogel implant). This technology allows for a "set it and forget it" treatment for wet AMD, which perfectly complements Sanofi’s gene therapy strategy of "reducing treatment burden."

The Bid: Sanofi reportedly offered $16 per share (approx. $2.3 billion) in September 2025. Following a rejection from the OCUL board, reports in January 2026 indicate Sanofi is preparing a higher, revised offer to secure the company.
+1

Kiwi

If most ( 70% ) of the patients on OCUL's drug can go 9 mths without another injection ...I'm not selling other than to recover part of initial investment.
That will be a game changer and there will probably be a bidding war .
It's all going to come down to results ( obviously ) ...is the data good enough for approval on this trial alone , or will the FDA want Sol-R ?? completed first .
So theres 3 main outcomes IMHO
Bad data
OK data but FDA wants 2nd trial completed before considering approval
Game changer data and FDA approves on 1 trial .

Sleven was more interested in EYPT IIRC ...not sure he ever added OCUL

Interesting day tomorrow ...good luck
Kiwi

As of February 16, 2026, Sanofi is actively pursuing an acquisition of Ocular Therapeutix (NASDAQ: OCUL) and is preparing a "sweetened," higher bid after a previous offer was rejected, reported by MarketMinute. The potential deal is centered on Ocular's lead drug candidate for wet AMD, Axpaxli, with pivotal Phase 3 results expected on February 17, 2026, according to FinancialContent.

Story about improved bid by Sanofi. $22-$28 if results are good.  I may decide to hold. 
https://business.times-online.com/times-online/article/marketminute-2026-2-16-sanofi-tightens-grip-on-ocular-therapeutix-with-revised-bid-as-pivotal-sol-1-trial-results-loom

Yep, over $11.  Will be setting my alarm early for Tuesday morning although my prostate has me up by that time anyway. Gonna sell half on positive news, and all of it if it skyrockets. I know a long time ago, Sleven said he would sell on news and not hold but the last time I had a message from him IIRC he said he didn’t have a position here. I might be wrong. Good luck to us all. 

RMB. You see the after hrs action on this .?

Kiwi

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 13, 2026

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026. Detailed data will be presented at the 49th Macula Society Annual Meeting between February 25 – 28, 2026.

Click here to register for the virtual webcast, which will begin at 8:00 AM ET.

The live and archived webcast can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcast will be archived for at least 30 days.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

$OCUL 🗞️

Not according to stock price today

Topline data release February 17.  So they must have data now.  Does that mean something bad?
https://ocutx.gcs-web.com/news-releases/news-release-details/ocular-therapeutixtm-announce-topline-data-sol-1-phase-3/

There is a post on Dew's values board about a story as to how EYPT's and OCUL's CEOs hate each other and the EYPT CEO saying OCUL has possession of trial data and not releasing it. 

Sleven, I sent you a private message. RMB

Suggest you watch for the KOD data this Sat

In the Phase 1b APEX study results being finalized this Saturday, Kodiak Sciences (KOD) is expected to emphasize that KSI-101 was "well tolerated" with a favorable early safety profile across all doses.
Key Safety Findings (APEX Phase 1b)
While full Week 24 safety tables will be presented this weekend, previous data from the study has already established several benchmarks:
No Serious Drug-Related Adverse Events: Earlier reports from the APEX study indicated that most participants at the top dose levels (5 mg and 10 mg) experienced no major safety issues, with no reports of serious side effects leading to treatment discontinuation.
Steroid-Free Advantage: A major highlight for KOD is that KSI-101 achieved its "drying effect" without typical steroid-related side effects, such as elevated intraocular pressure (glaucoma) or cataract formation.
Clean Inflammatory Profile: Despite targeting inflammatory pathways (IL-6), the drug itself did not trigger significant Intraocular Inflammation (IOI) in the initial cohorts, which was a concern for earlier generations of Kodiak’s platform.
Why Investors Watch Safety This Saturday
The primary reason this data matters is that Kodiak has already advanced the 5 mg and 10 mg doses into two massive Phase 3 studies (PEAK and PINNACLE).
10 mg Safety Confirmation: The 10 mg dose is exceptionally high for a liquid eye injection. If the Saturday data confirms that even the 10 mg group had zero cases of vasculitis or severe inflammation at 24 weeks, it would significantly de-risk the ongoing Phase 3 programs.
Comparison to Competitors: Maintaining a "safe profile" while achieving 90%+ retinal dryness would position KSI-101 as a potentially superior first-line treatment compared to steroid implants that often carry high ocular pressure risks.

KOD uses a thin needle MD's are comfortable with
OCUL uses a larger needle

Kiwi

Certainly agree!!  Still watching this and haven't jumped in yet.

It seems the downdraft has gotten worse since they announced the new hire - commercialization manager.  Meaning GIA

Thank you for the information. Definitely seems to be a little bit more high risk than I thought originally. Will take a few days to mull over the opportunity. Have a great weekend.

The risks ..I also posted this on Dew's board

The negative case for Ocular Therapeutix (OCUL) and its AXPAXLI (OTX-TKI) trials centers on heightened regulatory risk from a single-trial strategy, potential commercial irrelevance compared to entrenched competitors, and significant financial instability.
1. Heightened Regulatory & Clinical Risks
Single-Trial Dependency: Ocular recently pivoted to an accelerated NDA pathway relying primarily on the SOL-1 trial. This eliminates the safety net of a second confirmatory trial; any failure in SOL-1's topline results (expected Q1 2026) would likely be catastrophic for the company's valuation.
Real-World Efficacy Gap: The SOL-1 protocol uses specific "rescue criteria" (e.g., >5-letter loss in vision) that may not reflect real-world clinical practice, where doctors often treat at any sign of fluid. AXPAXLI's perceived "durability" might diminish significantly once used by clinicians with lower fluid tolerance.
Safety Uncertainty: There is a lack of long-term human data on bioresorption and between-eye variability. Potential risks include intraocular inflammation (IOI) or retinal vasculitis, which have plagued other long-acting therapies.

2. Commercial & Competitive Hurdles
Modest Practical Advantage: Even if AXPAXLI achieves a 6–12 month dosing cycle, it must compete with EYLEA HD and Vabysmo, https://investorshub.advfn.com/intelligencewhich already allow many patients to go 4–5 months between shots. The "net reduction" in office visits may not be compelling enough to convince doctors to switch to a newer, less-proven depot implant.
Payer Pushback: There is a risk that insurers may refuse premium pricing for AXPAXLI if its durability advantage is deemed marginal or if its safety profile is not significantly superior to biosimilars.
My emphasis

3. Deteriorating Financials
Massive Cash Burn: Ocular’s profit margin is approximately -382%, far below the industry average.
Operating Losses: The company’s adjusted operating margin has plummeted, reaching -472% in recent quarters as R&D costs for AXPAXLI ballooned.
Insider Sentiment: Corporate insider activity has turned negative recently, with an increase in shares being sold by company insiders.

These insider sales are not huge IMHO.
Market seems to think the data won't be good enough to warrant commercialization .
May add to my small position as a small spec
JMO
Good luck
Kiwi

Good day!!  Been watching this company for some time now.  I was considering jumping in at the current PPS.  Any comments & or recommendations?
Thank you in advance.Rich

I got stopped out of most of my OCUL position ...may revisit later
Kiwi

Well I guess thats how the markets taking it .
It's a move they have to make to preserve their options ....and he seems like the right guy for the job
Kiwi

Well this might put the kibosh on any BO talk:
https://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-appoints-david-w-robinson-global-chief/

Kiwi. Home and had a little time to look at it. FULC has sold off pretty much as much as OCUL has. Although EYPT has sold off some, it is not to the degree that OCUL has. Still undecided whether to grab some EYPT. If we see some gains in OCUL though, I will lighten up some.

Only a brief note as I am in Canada this weekend.  Still in FULC.  

After some more DD ...I may hedge my OCUL position with some EYPT ....which has pulled back recently .
Are you in FULC ?...some more data by late February I think
Kiwi

Thx ...yes some very informed posters on that board .
I think Worstluck prefers EYPT ...IIRC .
I'm holding thru data readout . Theres obvious risks here and I have no edge on insight ( as I think I may have in some areas of UNCY ) ,,,so positioned accordingly .
Kiwi

FWIW, a lot of discussion about OCUL on Dew's values board the last couple of days.  

Its up to the P 3 data ,,,due this Qt
Kiwi

Thanks Kiwi. Well, there you have it. RBC analyst Walter says it makes sense and Feuerstein says it doesn't.

jbog
Re: xavierprivas post# 256810
Thursday, January 15, 2026 5:55:06 PM
Post# of 256813
Shares of Ocular Therapeutix (OCUL) launched and then yo-yoed Thursday on reports Sanofi (SNY) is preparing an improved bid to buy it.

The rumored deal, reported by French newspaper La Lettre, comes as no surprise, RBC Capital Markets analyst Lisa Walter said in a report. Chief Executive Pravin Dugel previously sold Iveric Bio to Astellas Pharma (ALPMY) for $5.9 billion in 2023. And Ocular is expected to have updated test results in wet age-related macular degeneration sometime this quarter.

"Plus (with) the potential to file with the FDA on single trial (vs. 2 historically), we think the timing makes sense," Walter said, referencing reports the Food and Drug Administration may soon require only one Phase 3 study to clinch approval.

Ocular Therapeutix is working on treatments for a number of eye diseases, including diabetic retinopathy, wet AMD and retinal vein occlusion. Taken together, these conditions affect roughly 12.3 million people in the U.S., Ocular says on its website.

Ocular stock surged as much as 17.7% to 13.03 in morning trades before sliding into the red. Shares ultimately closed with a 1.9% gain at 11.28. Meanwhile, Sanofi stock slipped 0.9% to 47.47.

Can Ocular Help Replace Dupixent?
For Sanofi, the rumored deal makes a lot of sense, Walter said. The company previously offered up $16 a share in a bid to buy Ocular Therapeutix. Ocular turned it down in September when shares traded around 10.50.

A new deal could land somewhere in the range of $30 a share, she said. But that depends on what the updated test results look like in wet AMD and whether there's more than one buyer.. ( my emphasis )

"For SNY, there is a need to replace Dupixent revenue which is facing (loss of exclusivity) in 2031 (consensus estimates suggest 2025 revenue of $18.1b to SNY) and entering into the $15b neovascular/diabetic eye disease market could help," she said.

Dupixent, which Sanofi partners on with Regeneron Pharmaceuticals (REGN), treats inflammatory conditions like eczema and asthma. It's a massive blockbuster drug for both companies.

Walter kept her outperform rating and 30 price target on Ocular Therapeutix stock.

Adam Feuerstein ✡️
@adamfeuerstein
Is there a single person feeding La Lettre fake biotech takeover tips, or is this a group effort? The stock manipulation is brazen.

First, we learn all the $ABVX $LLY French Ministry speculation was fake, now today it's $SNY $OCUL

The story explains Sanofi's interest in "combination therapies" --> Dextenza + Dupixent? What the f--k? Dextenza is a tiny eye implant, Dupixent is an injectable. What are you combining?

The La Lettre story doesn't even mention Axpaxli or the upcoming SOL-1 ph3 study readout.

I think $OCUL is interesting and if SOL-1 hits, the company could be sold. In fact, I wrote that in early January given CEO Pravin Dugel's track record selling Iveric to Astellas.

But, please, look at how $OCUL traded at the end of Wednesday.

Kiwi

Well we dont know the P3 data yet ...or if any adverse events have shown up in that data.
There are problems with Eylea that are only now becoming more evident

Inflammation Studies: A May 2025 study suggested that intraocular inflammation may be more common than originally reported in clinical trials, emphasizing the need for early follow-up exams.

Thats for Eylea


A potential acquisition of Ocular (OCUL) is expected to give the Paris-based pharma giant a beachhead in wet age-related macular degeneration ((wet AMD)), the most common cause of severe vision loss among older adults.

Ocular's (OCUL) tyrosine kinase inhibitor Axpaxli is currently undergoing late-stage development for wet AMD across two studies called SOL-1 and SOL-R, which are scheduled to report topline data in Q1 2026 and H1 2027, respectively.


Kiwi

I'm waiting for the OCUL P3 data ...due this Qt.
If thats as good as hoped for ......they will want roughly $18-$20 a share ...my WAG ....even if they agreed to sell.
Sanofi definitely has a hole in their pipeline they need to fill ...so will be motivated
JMO
Kiwi

What is hilarious about today - as you are aware in the last couple of days I was thinking of moving some OCUL money into RZLT or something else - is when I woke up this morning and saw it over $13 my first thought was - great I can sell some here. But before doing so I decided to check the news and saw the story about Sanofi, so I held off. Heck if I would have sold I could now if I wanted to bought it back almost 2 1/2 bucks lower.